{"schema_version":"secwatch.filing_event.v1","accession":"0001099800-23-000042","form_type":"8-K","ticker":"EW","cik":"0001099800","company_name":"Edwards Lifesciences Corp","filed_at":"2023-12-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.219557+00:00","generated_at":"2026-06-07T16:00:26.131483+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Edwards plans tax-free spin-off of Critical Care, issues 2024 sales guidance $6.3-6.6B","bullets":["Edwards plans tax-free spin-off of Critical Care at end of 2024; Katie Szyman to be CEO of new company.","2024 guidance: sales $6.3-6.6B (8-10% constant currency growth), adjusted EPS $2.70-2.80.","2024 TAVR sales $4.0-4.3B (8-10% growth); TMTT sales $280-320M.","Board authorized $1B additional share repurchase authorization.","Clinical milestones: PROGRESS enrollment complete early 2024, EARLY TAVR data at TCT 2024, EVOQUE US approval mid-2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001099800-23-000042","json":"https://secwatch.observer/filing/0001099800-23-000042.json","markdown":"https://secwatch.observer/filing/0001099800-23-000042.md","text":"https://secwatch.observer/filing/0001099800-23-000042.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1099800/000109980023000042/0001099800-23-000042-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1099800/000109980023000042/ew-20231207.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T16:00:26.131483+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}